Similar enhancement of TCXCR4 tumor control was observed when the above GvT model was adapted by switching of the site of tumor inoculation to unilateral left-sided intratibial injections of 5 × 105 A20 cells (expressing human CD34 as a marker, huCD34.A20) before transfer, 2 days later, of 1 × 106 CD8+ allo-TCXCR4 or allo-TControl i.v., or no T cells. The gene discussed is CD34; the disease is neoplasm.